Patents Assigned to SYNIMMUNE GMBH
  • Bispecific antibody molecule
    Patent number: 9718893
    Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 1, 2017
    Assignee: SYNIMMUNE GMBH
    Inventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest
  • Anti-FLT3 antibodies
    Patent number: 9023996
    Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Synimmune GmbH
    Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung
  • BISPECIFIC ANTIBODY MOLECULE
    Publication number: 20150119555
    Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Application
    Filed: November 12, 2012
    Publication date: April 30, 2015
    Applicant: SYNIMMUNE GMBH
    Inventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest